NCT03740126Completed
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy; a Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to improve early detection of treatable relapse of lung cancer and thereby improve survival and quality of life for the patients. The investigators will perform a multicenter, randomized controlled trial to 1) assess if surveillance with whole body Positron Emission Tomography combined with Computer Tomography (PET/CT) including the brain can increase the number of treatable relapses and 2) concurrently collect liquid biopsies for later analysis, potentially enabling even earlier and minimally invasive detection and characterization of relapse.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 750 (actual)
- First submitted
- 25 Oct 2018
- Start date
- 25 Oct 2018
- Primary completion date
- 1 Sept 2023
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Diseases
- Lung cancer
- NCT number
- NCT03740126
What you commit to
- Study type: Interventional
- Participants enrolled: 750
- From 25 Oct 2018 to the primary completion date, 1 Sept 2023
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient, whose disease has progressed within the first 3 months after cancer treatment, e.g. confirmed progressive disease on CT.
- Dementia, mental alteration, severe psychiatric disease or other circumstances that can compromise informed consent from the patient and/or adherence to the protocol and the monitoring of the trial
Other
- Persons deprived of liberty or under guardianship or curators
- Pregnant or breastfeeding women
- Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention, whereas studies on late effects will not preclude participation in SUPE-R. Participation in protocols related only to initial treatment will not preclude participation in SUPE-R. Cases of doubt will be settled by the steering committee.
Who the study is looking for
- Patient with non-small cell lung cancer (NSCLC), proven by cytology or histology
- Patient in clinical stages I-III
- Age≥ 18 years
- Performance status ≤ 2 at the time of referral to therapy
- Patient referred for definitive treatment (e.g. surgery, surgery followed by adjuvant chemotherapy, concomitant radio-chemotherapy, conventional or stereotactic radiotherapy or radiofrequency ablation).
- Patient has given his/her written informed consent before any specific procedure from protocol
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
| Gentofte Hospital Coordinator of this site? Confirm its status | Gentofte Municipality | Denmark | Unknown status |
| Herlev Hospital Coordinator of this site? Confirm its status | Herlev | Denmark | Unknown status |
Related publications
- Diagnostic Accuracy of [18F]FDG PET/CT versus CT for NSCLC Surveillance: Secondary Analysis of a Randomized Clinical Trial.Clin Lung Cancer · 2026 · PMID 41387040
This page is information, not medical advice. Discuss any trial with your doctor.